The G-MASLD project with 18,759 biopsy-confirmed MASLD patients from 41 countries has been carried out by members of GNC. The project continues to provide critical data about MASLD/MASH and NITs from real world practices. In this analysis of G-MASLD data, the diagnostic accuracy and performance of NITs were influenced by patient characteristics. FIB-4 performance declined with younger and older age as well as presence of type 2 diabetes, while liver stiffness measurement was mainly affected by obesity. Imaging-based and clinical composite tests, especially Agile-3+ and Agile-4 showed more stable performance across subgroups.
